HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ICCC
ImmuCell Corporation
ICCC's fundamentals are strong: its operating margin rose 6 points to 14% and revenue grew 20%, though earnings per share fell 34%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ICCC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
ICCC's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ICCC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $4.26 | -58% |
| Current | 54x | $10.22 | — |
| Fair | 83x | $15.70 | +54% |
| Expensive | 809x | $154 | +1403% |
Historical ranges are pointers, not guarantees.
ICCC's PE is 54x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over ICCC on the outlook, with more favorable revenue and profitability expectations.
ICCC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect ICCC's earnings and revenue to decline, with profitability weakening.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ICCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.19 | -34% |
| Q2 2026 | $0.07 | -68% |
| Q1 2026 | -$0.07 | -$0.03 |
| Q4 2025 | -$0.12 | +$0.14 |
| Q3 2025 | $0.29 | +$0.79 |
| Q2 2025 | $0.22 | +$0.75 |
| Q1 2025 | -$0.04 | +$0.47 |
| Q4 2024 | -$0.26 | +$0.49 |
ICCC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ICCC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ICCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8M | +46% |
| Q2 2026 | $7.2M | +12% |
| Q1 2026 | $10.4M | +28% |
| Q4 2025 | $7.6M | -1.6% |
| Q3 2025 | $5.5M | -8.4% |
| Q2 2025 | $6.4M | +18% |
| Q1 2025 | $8.1M | +11% |
| Q4 2024 | $7.8M | +52% |
ICCC's revenue is growing: $8M last quarter, up 46% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | +12 points |
| Q2 2026 | 27% | +18 points |
| Q1 2026 | 19% | +5.2 points |
| Q4 2025 | -0.8% | -8.8 points |
| Q3 2025 | 0.4% | +9.9 points |
| Q2 2025 | 8.8% | +34 points |
| Q1 2025 | 14% | +18 points |
| Q4 2024 | 8% | +28 points |
ICCC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ICCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$589.4K | +$1.2M |
| Q2 2026 | $2.3M | +58% |
| Q1 2026 | $3.4M | +173% |
| Q4 2025 | $310.2K | +$509.5K |
| Q3 2025 | -$1.8M | -$1M |
| Q2 2025 | $1.4M | +207% |
| Q1 2025 | $1.2M | +258% |
| Q4 2024 | -$199.3K | +$605.1K |
ICCC has burned cash in most quarters: $5M over the past year, about eight times what it generated the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ICCC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ICCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +108K shares |
| 1 year | +2.8% | +252K shares |
| 3 years | +20% | +1.6M shares |
| 5 years | +19% | +1.5M shares |
| Available history | +36% | +2.5M shares |
ICCC has 9M diluted shares, up 2.8% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ICCC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Very low |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 6.5x | High |
ICCC has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ICCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 34.9 | Neutral |
ICCC's weekly RSI is 56 (neutral) and its Stochastic is 35 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ICCC PE vs Healthcare Sector
| Metric | ICCC | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 26x | 108% above |
| PE % | 36 | 29 | 7 pts above |
ICCC is trading at 54x earnings, a 108% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ICCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 1.2% above |
| 20 week MA | $10.3 | 0.8% below |
| 50 week MA | $8.54 | 20% above |
| 100 week MA | $7.15 | 43% above |
| 200 week MA | $6.02 | 70% above |
ICCC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ICCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.90 | $6.25 | +28% |
| 2021 | $6.25 | $8.31 | +33% |
| 2022 | $8.31 | $6.23 | -25% |
| 2023 | $6.23 | $5.09 | -18% |
| 2024 | $5.09 | $4.98 | -2.2% |
| 2025 | $4.98 | $6.12 | +23% |
| 2026 YTD | $6.12 | $10.2 | +67% |
ICCC has the edge over HIMS on returns for 2026, with the stronger performance.